Related Experiment Video
Updated: Aug 11, 2026
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Bacillus Calmette-Guérin in superficial bladder cancer: consensus and controversies
P D Vegt1, F M Debruyne, A P van der Meijden
1Departments of Urology, Rijnland Hospital, Leiderdorp, The Netherlands.
Insights
Bacillus Calmette-Guérin (BCG) immunotherapy is effective for superficial bladder cancer via intravesical instillation. While maintenance therapy is superior, optimal dosage and toxicity reduction remain debated topics requiring further research.
Area of Science:
- Urology
- Immunotherapy
- Oncology
Background:
- Superficial bladder cancer (SBC) treatment often involves Bacillus Calmette-Guérin (BCG) immunotherapy.
- Consensus and controversies exist regarding optimal BCG therapy protocols for SBC.
Purpose of the Study:
- To review current consensus and existing controversies in Bacillus Calmette-Guérin (BCG) immunotherapy for superficial bladder cancer.
- To evaluate optimal administration routes, BCG strains, treatment schedules, dosage, and toxicity management.
Main Methods:
- Systematic review and analysis of existing literature on BCG immunotherapy for superficial bladder cancer.
- Evaluation of data regarding BCG administration routes, strains, schedules, dosage, and adverse events.
Main Results:
- Intravesical instillation is the accepted optimal route for BCG administration.
- No single BCG substrain demonstrated superiority over others.
- Maintenance therapy significantly outperforms induction therapy alone for superficial bladder cancer.
- Optimal BCG dosage and methods for reducing treatment toxicity remain subjects of ongoing debate and require further investigation.
Conclusions:
- Bacillus Calmette-Guérin (BCG) immunotherapy is a highly effective treatment for superficial bladder cancer.
- While intravesical instillation and maintenance therapy are established as optimal, further research is needed to define ideal dosage and mitigate toxicity.
- BCG immunotherapy is not universally effective for all patients with superficial bladder cancer.
Abstract:
In this overview, Bacillus Calmette-Guérin (BCG) immunotherapy in superficial bladder cancer items are discussed on which consensus has been reached and on which controversies exist. The evaluation of the optimal route of administration has shown that intravesical instillation of BCG alone is accepted as the best route of administration. In searching for the appropriate BCG strain, the analysis of the results of 6 substrains has made clear that no particular strain has shown superiority over others. In finding the optimal treatment schedule there is strong evidence that maintenance therapy is superior to induction therapy alone. No consensus has been reached about the optimal dose for BCG therapy nor about how the toxicity of BCG treatment can be reduced. Although some reports have stated that BCG immunotherapy is superior to chemotherapy for the treatment of patients with superficial bladder cancer, more data are needed to prove this statement. In conclusion, although BCG has been proven to be very effective in the treatment of patients with superficial bladder cancer, it is certainly not a panacea for all patients with superficial bladder cancer.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
06:12Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
Published on: May 29, 2015
Related Concept Videos
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
01:30Urinary Tract Calculi III: Medical Management
01:25Urinary Tract Calculi VI: Surgical Management
01:22Imaging Studies VI: Voiding Cystourethrography and Cystography